For patients with center-involving diabetic macular edema and good visual acuity, the Diabetic Retinopathy Clinical Research (DRCR) Retina Network’s randomized clinical trial Protocol V found no significant difference in vision loss between prompt anti–vascular endothelial growth factor (anti-VEGF) treatment and initial observation.1 Protocol V raises the important teleological question as to what the goal should be in treating macular edema. For patients with good vision and center-involving diabetic macular edema, is there an anti-VEGF treatment strategy that is not too much or too little but just right?

This content was originally published here.